WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005014822) NOVEL THERAPEUTIC FUSION PROTEINS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/014822    International Application No.:    PCT/EP2004/051715
Publication Date: 17.02.2005 International Filing Date: 04.08.2004
IPC:
A61K 38/00 (2006.01), C07K 14/47 (2006.01), C07K 14/74 (2006.01), C07K 14/79 (2006.01), C12N 15/62 (2006.01)
Applicants: Applied Research Systems ARS Holding N.V. [NL/NL]; Pietermaai 15, Curacao (AN) (For All Designated States Except US).
YANG, Meija [US/US]; (US) (For US Only)
Inventors: YANG, Meija; (US)
Agent: SERONO INTERNATIONAL S.A. INTELLECTUAL PROPERTY; 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH)
Priority Data:
60/492,397 04.08.2003 US
Title (EN) NOVEL THERAPEUTIC FUSION PROTEINS
(FR) NOUVELLES PROTÉINES DE FUSION THÉRAPEUTIQUES
Abstract: front page image
(EN)The present invention provides novel therapeutic molecules called Culling Fusion Proteins (CFPs) that allow the continuous removal of therapeutic targets from extracellular space by exploiting the endosome/lysosome intracellular degradation pathway, and the exocytotic pathway in a combined manner. The products of the invention, by appropriately utilizing the cellular endocytosis and exocytosis mechanism, can be recycled multiple times by cells to eliminate undesired molecules, therefore such therapeutic molecules can be administered at low concentration.
(FR)Nouvelles molécules thérapeutiques appelées protéines de fusion de triage (CFP) qui permettent l'élimination en continu de cibles thérapeutiques de l'espace extracellulaire par exploitation de la voie de dégradation intracellulaire endosome / lysosome et de la voie exocytotique de manière combinée. L'utilisation appropriée du mécanisme cellulaire de l'endocytose et de l'exocytose permet le recyclage multiple des produits selon la présente invention par les cellules pour éliminer les molécules indésirables, lesdites molécules thérapeutiques pouvant donc être administrées à une faible concentration.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)